MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-101238-PIP01-23-M01

Scope of the Application

Active Substance(s)

UPADACITINIB

Condition(s)

Treatment of ulcerative colitis

Pharmaceutical Form(s)

Prolonged release tablet; Age-appropriate oral pharmaceutical form

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

AbbVie Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AbbVie Ltd submitted to the licensing authority on 28/11/2023 11:21 GMT an application for a Modification

The procedure started on 28/02/2024 12:01 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101238-PIP01-23-M01

Of 13/03/2024 10:06 GMT

On the adopted decision for UPADACITINIB (MHRA-101238-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for UPADACITINIB, Prolonged release tablet; Age-appropriate oral pharmaceutical form , ORAL USE .

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, Maidenhead, UNITED KINGDOM, SL64UB

ANNEX I

1. Waiver

1.1 Condition:

Treatment of ulcerative colitis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth 2 years of age. Pharmaceutical form(s): Prolonged-release tablet, Age-appropriate oral pharmaceutical form Route(s) of administration: ORAL USE Reason for granting waiver: On the grounds the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of ulcerative colitis.

2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients with moderately severely acute ulcerative colitis.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Prolonged-release tablet Age-appropriate oral pharmaceutical form

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Age-appropriate oral solid dosage form (dispersible tablet or multi-particulate granules) or age-appropriate oral liquid dosage form.
Non-Clinical Studies	2	Study 2 Dose range-finding juvenile toxicity study. Study 3 Definitive juvenile toxicity study to evaluate toxicity and impact of upadacitinib on neonatal/juvenile development.
Clinical Studies	1	Study 4 (M14-658) Double-blind safety, efficacy, and pharmacokinetic study with an open label induction phase of upadacitinib in children from 2 to less than 18 years with moderately to severely active UC, who have had an inadequate response or been intolerant to corticosteroids, immunosuppressants, and/or biologic therapy, or have medical contraindications to such therapies.
Extrapolation, Modeling & Simulation Studies	1	Study 5 Population PK modelling and simulation study to determine the dose of upadacitinib in children from 2 to less than 18 years of age with ulcerative colitis.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/09/2028
Deferral of one or more studies contained in the paediatric investigation plan:	Yes